Skip to main content
Equibles
INKT logo

INKT · MiNK Therapeutics, Inc. · Earnings Call Transcripts & Audio

Track INKT — free

Use INKT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research INKT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$12.55 +0.29 (+2.37%) At close · Sep 30
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Because the completion of anticipated funding is not entirely within the Company's control, the Company is required to disclose that substantial doubt exists about its ability to continue as a going concern for a period of one year after the date of filing of this Quarterly Report on Form 10-Q.”
View the 10-Q filed Aug 13, 2026
Market Cap
$62.15M
Shares
5.10M
Volume · Sep 30 61.14K Avg daily vol (3M) 12.81K

MiNK Therapeutics, Inc. Earnings Call Transcripts

Quarterly earnings calls for MiNK Therapeutics, Inc. (INKT), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →
Earnings call
FY26 · Q2
2026-08-13
MiNK Therapeutics, Inc. (INKT) Q2 2026 Earnings Call Transcript
Confident tone Agent 797 Phase 2 in ARDS / acute lung injury Multi-drug resistant infections and biothreat Named Patient paid access program in Brazil
Diluted EPS
$-0.62
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-15
MiNK Therapeutics, Inc. (INKT) Q1 2026 Earnings Call Transcript
Confident tone ARDS / Severe Acute Lung Injury Program INKT Cell Therapy Platform / Agent 797 Biomarkers & Mechanistic / Translational Findings
Diluted EPS
$-0.57
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q3
2025-12-08
MiNK Therapeutics, Inc. (INKT) Q3 2025 Earnings Call Transcript
Confident tone AGENT-797 Clinical Data in Solid Tumors Safety Profile of iNKT Cell Therapy Platform Biology and Mechanism
Diluted EPS
$-0.65
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
MiNK Therapeutics, Inc. (INKT) Q2 2025 Earnings Call Transcript
Confident tone iNKT Platform & Lead Candidate agenT-797 GvHD Prophylaxis Program ARDS / Respiratory Distress
Diluted EPS
$-1.06
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-15
MiNK Therapeutics, Inc. (INKT) Q1 2025 Earnings Call Transcript
Confident tone GvHD program and NIAID funding Solid tumor clinical data (gastric and testicular) Regulatory pathway and FDA engagement
Diluted EPS
$-0.70
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-18
MiNK Therapeutics, Inc. (INKT) Q4 2024 Earnings Call Transcript
Confident tone Clinical Pipeline / 797 in Oncology Next-Generation Programs (PRAME-TCR, 215, Neoantigens) Graft versus Host Disease (GvHD) Program & NIAID Funding
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-14
MiNK Therapeutics, Inc. (INKT) Q3 2024 Earnings Call Transcript
Confident tone Graft-versus-Host Disease program iNKT cell platform and manufacturing efficiency Agent 797 in gastric cancer (Phase 2)
Diluted EPS
$-0.46
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
MiNK Therapeutics, Inc. (INKT) Q2 2024 Earnings Call Transcript
Confident tone AgenT-797 in ARDS Bispecific engagers and iNKT combination MiNK-215 CAR-iNKT preclinical
Diluted EPS
$-0.73
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
MiNK Therapeutics, Inc. (INKT) Q1 2024 Earnings Call Transcript
Confident tone MiNK-215 CAR-iNKT (FAP) preclinical and discovery progress agenT-797 Phase II gastric cancer trial Combination strategy with checkpoint / T-cell activators
Diluted EPS
$-1.10
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-21
MiNK Therapeutics, Inc. (INKT) Q4 2023 Earnings Call Transcript
Confident tone iNKT cell platform and manufacturing capabilities Phase 2 gastric cancer trial with agenT-797 Colorectal cancer MSS opportunity with bot/bal
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-09
MiNK Therapeutics, Inc. (INKT) Q3 2023 Earnings Call Transcript
Diluted EPS
$-1.50
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
MiNK Therapeutics, Inc. (INKT) Q1 2023 Earnings Call Transcript
Diluted EPS
$-1.70
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-21
MiNK Therapeutics, Inc. (INKT) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
MiNK Therapeutics, Inc. (INKT) Q3 2022 Earnings Call Transcript
Diluted EPS
$-1.90
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
MiNK Therapeutics, Inc. (INKT) Q2 2022 Earnings Call Transcript
Diluted EPS
$-1.80
Audio Transcript Slides 8-K10-Q
Showing 1–15 of 15 earnings calls
Key facts CIK 1840229 CUSIP 603693201 13F (30d) 1 filings 1 filers Visit website Investor relations